(Información remitida por la empresa firmante)

Hannah DeresiewiczStern Investor Relations, Inc.

Hannah.deresiewicz@sternir.com

Para Pierre Fabre Laboratories

Contacto para los medios:

Laure Sgandurra

Pierre Fabre Laboratories

Laure.sgandurra@pierre-fabre.com

[1] The Prevalence of EGFR Mutation in Patients with Non-Small Cell Lung Cancer, Oncotarget, Octubre de 2016

[2] EGFR Mutation Incidence in Non-Small Cell Lung Cancer, J Cancer Res., Agosto de 2015

[3] Molecular Epidemiology of EGFR Mutations in Asian Patients, PLoS ONE, Noviembre de 2015

[4] EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives, Biomarker Research, Abril de 2022

Logo -- https://mma.prnewswire.com/media/2046443/Pierre_Fabre_Scorpion_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/scorpion-therapeutics-y-pierre-fabre-laboratories-anuncian-la-dosis-al-primer-paciente-del-ensayo-clinico-de-fase-12-de-stx-721-un-inhibidor-del-exon-20-del-egfr-selectivo-de-mutantes-para-el-tratamiento-del-301950724.html